Gyeongnam Biopharma Decides on 10 Billion KRW Paid-in Capital Increase
[Asia Economy Reporter Lee Gwan-joo] Gyeongnam Biopharma announced on the 10th that it has decided to conduct a paid-in capital increase through a third-party allotment to raise 10 billion KRW in operating funds. The new shares consist of 5,194,805 common shares, with a par value of 500 KRW per share.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- [Breaking] Park Sukeun, Central Labor Relations Commission Chair: "Some Gaps Narrowed Between Samsung Electronics Labor and Management"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "I Take Full Responsibility"... Chung Yongjin Issues Direct Apology for Starbucks 'May 18 Controversy' (Update)
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
